AI
By
Can Sanofi’s $380 Million AI Investment in 2025 — Bolstered by Strategic Partnerships — Drive Breakthroughs in Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Sanofi S.A. made significant investments in artificial intelligence (AI) across discovery, clinical…
Can Roche’s $420 Million AI Investment in 2025 — Backed by Strategic AI Deals — Boost Discovery, R&D, and Commercial Advantage in 2026?
Global – December 31, 2025 — Roche Holding AG, a global leader in pharmaceuticals and diagnostics, significantly expanded…
Can Novartis’ $480 Million AI Investment in 2025 — Bolstered by Strategic AI Deals — Accelerate Discovery, R&D, and Commercial Leadership in 2026?
Global – December 31, 2025 — Novartis International AG significantly expanded its investment in artificial intelligence (AI) across…
Can Johnson & Johnson’s $350 Million AI Investment in 2025 Transform Drug Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Johnson & Johnson significantly expanded its use of artificial intelligence (AI) across…
Will Eli Lilly’s 2025 Earnings Prove That AI Is the Hidden Engine Behind Its Next Phase of Scale?
Late January 2026 | Full-Year 2025 Earnings Preview | AI-Driven Biopharma Leadership Eli Lilly is set to report…
Can AbbVie’s 2025 Earnings Prove Its Post-Humira Portfolio Is Built for the Next Decade?
Late January 2026 | Full-Year 2025 Earnings Preview | Biopharma Growth Strategy AbbVie is set to report its…
